Back to search
FDAFDA · Food and drugs·Recall number D-0144-2026

Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88.

Published November 5, 2025 · Recall initiated: October 28, 2025

Summary

FDA records drug Class II recall D-0144-2026, published November 5, 2025 and initiated October 28, 2025. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Ongoing; Reported quantity: N/A; Lot: Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25®C, 60%RH) for Lisdexamfetamine dimesylate capsules.

What to do

Voluntary: Firm initiated · Letter

Get an email if LISDEXAMFETAMINE DIMESYLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LISDEXAMFETAMINE DIMESYLATE
Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
U.S Nationwide.
Lot
Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88. recalled?

Yes. FDA published recall D-0144-2026 on November 5, 2025. Reported hazard: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25®C, 60%RH) for Lisdexamfetamine dimesylate capsules.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LISDEXAMFETAMINE DIMESYLATE.